Selective increase of NMDA-sensitive glutamate binding in the striatum of Parkinson's disease, Alzheimer's disease, and mixed Parkinson's disease/Alzheimer's disease patients: an autoradiographic study

Abstract

Parkinson's disease (PD) and Alzheimer's disease (AD) may share certain abnormalities since a subset of PD patients suffer from dementia, and some AD individuals show extrapyramidal symptoms. In vitro quantitative autoradiography was used to examine different subtypes of excitatory amino acid (EAA) receptors (NMDA, KA, and AMPA) and dopamine transporter sites in the striatum (caudate, putamen) and nucleus accumbens (NAc) from idiopathic PD, pure AD, and mixed PD/AD patients. PD and AD groups, and to a lesser extent the PD/AD groups, showed substantially increased binding to NMDA receptors in the striatum and NAc. No statistically significant changes in binding to KA and AMPA receptors were found in any patient group. 3H-mazindol binding to dopamine transporter sites was significantly decreased in the striatum and NAc of PD and PD/AD patients, but only in the putamen and NAc of AD patients. The data indicate that (1) the majority of striatal EAA receptors are not located on dopaminergic nigrostriatal nerve terminals, and (2) elevated binding to striatal NMDA receptors correlates with binding to dopamine transporter sites in PD patients, but not in AD and PD/AD individuals. Thus, the mechanisms of NMDA receptor changes in the striatum of AD and PD patients may be different. However, it is postulated that increased binding to NMDA receptors in Parkinson and Alzheimer striatum occurs in response to an insult(s) within the striatothalamocortical circuits and that this may contribute to the clinical similarities described for subsets of PD and AD patients.

Does Ketamine-Mediated N-methyl-D-aspartate Receptor Antagonism Cause Schizophrenia-like Oculomotor Abnormalities?

“…NMDA receptors located in human cortical (Conti et al 1997), striatal (Ulas et al 1994), and cerebellar (Jansen et al 1991) regions might be functionally important for smooth pursuit. Ketamine antagonism of NMDA receptors in any of these areas may have been responsible for the portion of the smooth pursuit impairment not attributable to frank nystagmus.…”

Chronic NMDA Administration Increases Neuroinflammatory Markers in Rat Frontal Cortex: Cross-Talk Between Excitotoxicity and Neuroinflammation

“…lamotrigine). A study also has reported increased NMDA-sensitive glutamate binding in the striatum of Alzheimer and Parkinson patients [20], further indicating a role for glutamate excitotoxicity in neurodegenerative diseases.…”

Investigation of the Effect of Cycloserine on Motor Function in a Rat Model of Parkinson’s disease

“…Glutamatergic activity and NMDA receptor density in the basal ganglia increase in patients with PD (23). Cycloserine is able to pass blood-brain barrier and enter the brain tissue where it acts as a partial agonist by binding to the binding site of the NMDA receptor (9).…”